| Sinusitis (acute): antimicrobial prescribing | NG79 | | |
| Cataracts in adults: management | NG77 | | |
| Cystic fibrosis: diagnosis and management | NG78 | | |
| Hepatitis B (chronic): diagnosis and management | CG165 | | |
| Tofacitinib for moderate to severe rheumatoid arthritis | TA480 | | |
| Immunosuppressive therapy for kidney transplant in adults | TA481 | | |
| Immunosuppressive therapy for kidney transplant in children and young people | TA482 | | |
| Child abuse and neglect | NG76 | | |
| Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee | TA477 | | |
| Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma | TA478 | | |
| Reslizumab for treating severe eosinophilic asthma | TA479 | | |
| Faltering growth: recognition and management of faltering growth in children | NG75 | | |
| Cetuximab and panitumumab for previously untreated metastatic colorectal cancer | TA439 | | |
| Intermediate care including reablement | NG74 | | |
| Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy | TA428 | | |
| Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab | TA357 | | |
| Pembrolizumab for advanced melanoma not previously treated with ipilimumab | TA366 | | |
| Fertility problems: assessment and treatment | CG156 | | |
| Sorafenib for treating advanced hepatocellular carcinoma | TA474 | | |
| Dimethyl fumarate for treating moderate to severe plaque psoriasis | TA475 | | |
| Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer | TA476 | | |
| Psoriasis: assessment and management | CG153 | | |
| Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck | TA473 | | |
| Vitamin D: supplement use in specific population groups | PH56 | | |
| Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) | TA468 | | |
| Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) | TA469 | | |
| Holoclar for treating limbal stem cell deficiency after eye burns | TA467 | | |
| Pemetrexed for the maintenance treatment of non-small-cell lung cancer | TA190 | | |
| Developmental follow-up of children and young people born preterm | NG72 | | |
| Cabozantinib for previously treated advanced renal cell carcinoma | TA463 | | |
| Baricitinib for moderate to severe rheumatoid arthritis | TA466 | | |
| Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition | CG32 | | |
| Adalimumab and dexamethasone for treating non-infectious uveitis | TA460 | | |
| Roflumilast for treating chronic obstructive pulmonary disease | TA461 | | |
| Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma | TA462 | | |
| Parkinson's disease in adults | NG71 | | |
| Constipation in children and young people: diagnosis and management | CG99 | | |
| Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people | TA455 | | |
| Ustekinumab for moderately to severely active Crohn's disease after previous treatment | TA456 | | |
| Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) | TA452 | | |
| Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) | TA453 | | |
| Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA454 | | |
| Eliglustat for treating type 1 Gaucher disease | HST5 | | |
| Etelcalcetide for treating secondary hyperparathyroidism | TA448 | | |
| Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease | TA449 | | |
| Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia | TA450 | | |
| Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia | TA451 | | |
| Spondyloarthritis in over 16s: diagnosis and management | NG65 | | |
| Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | TA444 | | |
| Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA445 | | |
| Idiopathic pulmonary fibrosis in adults: diagnosis and management | CG163 | | |
| Intravenous fluid therapy in adults in hospital | CG174 | | |
| Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine | TA440 | | |
| Ixekizumab for treating moderate to severe plaque psoriasis | TA442 | | |
| Obeticholic acid for treating primary biliary cholangitis | TA443 | | |
| Antisocial behaviour and conduct disorders in children and young people: recognition and management | CG158 | | |
| Alcohol-use disorders: diagnosis and management of physical complications | CG100 | | |
| Irritable bowel syndrome in adults: diagnosis and management | CG61 | | |
| Managing medicines for adults receiving social care in the community | NG67 | | |
| Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) | TA438 | | |
| Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) | TA240 | | |
| Patient group directions | MPG2 | | |
| Elotuzumab for previously treated multiple myeloma (terminated appraisal) | TA434 | | |
| Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) | TA435 | | |
| Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) | TA436 | | |
| Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) | TA437 | | |
| Mental health of adults in contact with the criminal justice system | NG66 | | |
| Ustekinumab for treating active psoriatic arthritis | TA340 | | |
| Ustekinumab for treating moderate to severe plaque psoriasis | TA180 | | |
| Migalastat for treating Fabry disease | HST4 | | |
| Everolimus for advanced renal cell carcinoma after previous treatment | TA432 | | |
| Apremilast for treating active psoriatic arthritis | TA433 | | |
| Healthcare-associated infections: prevention and control in primary and community care | CG139 | | |
| Osteoporosis: assessing the risk of fragility fracture | CG146 | | |
| Cerebral palsy in under 25s: assessment and management | NG62 | | |
| Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation | TA429 | | |
| Sofosbuvir–velpatasvir for treating chronic hepatitis C | TA430 | | |
| Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib | TA427 | | |
| Organ donation for transplantation: improving donor identification and consent rates for deceased organ donation | CG135 | | |
| Everolimus with exemestane for treating advanced breast cancer after endocrine therapy | TA421 | | |
| Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA422 | | |
| Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens | TA423 | | |
| Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer | TA424 | | |
| Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia | TA425 | | |
| Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia | TA426 | | |
| Hypothermia: prevention and management in adults having surgery | CG65 | | |
| Ticagrelor for preventing atherothrombotic events after myocardial infarction | TA420 | | |
| Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis | CG95 | | |
| Coexisting severe mental illness and substance misuse: community health and social care services | NG58 | | |
| Spasticity in under 19s: management | CG145 | | |
| Nivolumab for previously treated advanced renal cell carcinoma | TA417 | | |
| Dapagliflozin in triple therapy for treating type 2 diabetes | TA418 | | |
| Apremilast for treating moderate to severe plaque psoriasis | TA419 | | |
| Dapagliflozin in combination therapy for treating type 2 diabetes | TA288 | | |
| Physical health of people in prison | NG57 | | |
| Psychosis and schizophrenia in children and young people: recognition and management | CG155 | | |
| Elbasvir–grazoprevir for treating chronic hepatitis C | TA413 | | |
| Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma | TA414 | | |
| Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor | TA415 | | |
| Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion | TA409 | | |
| Talimogene laherparepvec for treating unresectable metastatic melanoma | TA410 | | |
| Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer | TA411 | | |
| Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases | TA412 | | |
| Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA406 | | |
| Pegaspargase for treating acute lymphoblastic leukaemia | TA408 | | |
| Secukinumab for treating active ankylosing spondylitis | TA407 | | |
| Multimorbidity: clinical assessment and management | NG56 | | |
| Harmful sexual behaviour among children and young people | NG55 | | |
| Mental health problems in people with learning disabilities: prevention, assessment and management | NG54 | | |
| Transition between inpatient mental health settings and community or care home settings | NG53 | | |
| Stable angina: management | CG126 | | |
| Acute upper gastrointestinal bleeding in over 16s: management | CG141 | | |
| Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel | TA391 | | |
| Bosutinib for previously treated chronic myeloid leukaemia | TA401 | | |
| Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin | TA402 | | |
| Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer | TA403 | | |
| Degarelix for treating advanced hormone-dependent prostate cancer | TA404 | | |
| Trifluridine–tipiracil for previously treated metastatic colorectal cancer | TA405 | | |
| Palliative care for adults: strong opioids for pain relief | CG140 | | |
| Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated | TA387 | | |
| Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts | TA399 | | |
| Nivolumab in combination with ipilimumab for treating advanced melanoma | TA400 | | |
| Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen | TA259 | | |
| Non-Hodgkin's lymphoma: diagnosis and management | NG52 | | |
| Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures | CG64 | | |
| Non-alcoholic fatty liver disease (NAFLD): assessment and management | NG49 | | |
| Oral health for adults in care homes | NG48 | | |
| Adalimumab for treating moderate to severe hidradenitis suppurativa | TA392 | | |
| Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia | TA393 | | |
| Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia | TA394 | | |
| Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer | TA395 | | |
| Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma | TA396 | | |
| Haematological cancers: improving outcomes | NG47 | | |
| Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes | TA390 | | |
| Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction | TA388 | | |
| Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer | TA389 | | |
| Controlled drugs: safe use and management | NG46 | | |
| Routine preoperative tests for elective surgery | NG45 | | |
| Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis | TA386 | | |
| Community engagement: improving health and wellbeing and reducing health inequalities | NG44 | | |
| Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) | TA23 | | |
| Transition from children's to adults' services for young people using health or social care services | NG43 | | |
| Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia | TA385 | | |
| Nivolumab for treating advanced (unresectable or metastatic) melanoma | TA384 | | |
| Fractures (non-complex): assessment and management | NG38 | | |
| Major trauma: assessment and initial management | NG39 | | |
| Major trauma: service delivery | NG40 | | |
| Spinal injury: assessment and initial management | NG41 | | |
| Sunlight exposure: risks and benefits | NG34 | | |
| TNF-alpha inhibitors for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA383 | | |
| Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated | TA377 | | |
| Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy | TA378 | | |
| Nintedanib for treating idiopathic pulmonary fibrosis | TA379 | | |
| Panobinostat for treating multiple myeloma after at least 2 previous treatments | TA380 | | |
| Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) | TA382 | | |
| Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | | |
| Guidance on the use of imatinib for chronic myeloid leukaemia | TA70 | | |
| Older people: independence and mental wellbeing | NG32 | | |
| Care of dying adults in the last days of life | NG31 | | |
| Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis | TA373 | | |
| Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy | TA374 | | |
| Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears | TA369 | | |
| Bortezomib for previously untreated mantle cell lymphoma | TA370 | | |
| Transition between inpatient hospital settings and community or care home settings for adults with social care needs | NG27 | | |
| Children's attachment: attachment in children and young people who are adopted from care, in care or at high risk of going into care | NG26 | | |
| Ledipasvir–sofosbuvir for treating chronic hepatitis C | TA363 | | |
| Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C | TA365 | | |
| Vortioxetine for treating major depressive episodes | TA367 | | |
| Blood transfusion | NG24 | | |
| Older people with social care needs and multiple long-term conditions | NG22 | | |
| Developing and updating local formularies | MPG1 | | |
| Tolvaptan for treating autosomal dominant polycystic kidney disease | TA358 | | |
| Idelalisib for treating chronic lymphocytic leukaemia | TA359 | | |
| Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) | TA362 | | |
| Home care: delivering personal care and practical support to older people living in their own homes | NG21 | | |
| Coeliac disease: recognition, assessment and management | NG20 | | |
| Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy | TA352 | | |
| Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) | TA353 | | |
| Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism | TA354 | | |
| Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use | NG15 | | |
| Naloxegol for treating opioid‑induced constipation | TA345 | | |
| Aflibercept for treating diabetic macular oedema | TA346 | | |
| Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer | TA347 | | |
| Everolimus for preventing organ rejection in liver transplantation | TA348 | | |
| Secukinumab for treating moderate to severe plaque psoriasis | TA350 | | |
| Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal) | TA351 | | |
| Omalizumab for previously treated chronic spontaneous urticaria | TA339 | | |
| Vedolizumab for treating moderately to severely active ulcerative colitis | TA342 | | |
| Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism | TA341 | | |
| Lower urinary tract symptoms in men: management | CG97 | | |
| Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia | TA343 | | |
| Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges | NG11 | | |
| Violence and aggression: short-term management in mental health, health and community settings | NG10 | | |
| Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome | TA335 | | |
| Empagliflozin in combination therapy for treating type 2 diabetes | TA336 | | |
| Rifaximin for preventing episodes of overt hepatic encephalopathy | TA337 | | |
| Excess winter deaths and illness and the health risks associated with cold homes | NG6 | | |
| Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes | NG5 | | |
| Safe midwifery staffing for maternity settings | NG4 | | |
| Bladder cancer: diagnosis and management | NG2 | | |
| Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) | TA334 | | |
| Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy | TA329 | | |
| Sofosbuvir for treating chronic hepatitis C | TA330 | | |
| Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment | TA333 | | |
| Eculizumab for treating atypical haemolytic uraemic syndrome | HST1 | | |
| Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma | TA269 | | |
| Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism | TA327 | | |
| Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy | TA323 | | |
| Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block | TA324 | | |
| Nalmefene for reducing alcohol consumption in people with alcohol dependence | TA325 | | |
| Imatinib for the adjuvant treatment of gastrointestinal stromal tumours | TA326 | | |
| Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block | TA88 | | |
| Gallstone disease: diagnosis and management | CG188 | | |
| Oral health: local authorities and partners | PH55 | | |
| Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma | TA321 | | |
| Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence | CG115 | | |
| Drug allergy: diagnosis and management | CG183 | | |
| Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis | TA320 | | |
| Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen | TA316 | | |
| Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes | TA317 | | |
| Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma | TA319 | | |
| Safe staffing for nursing in adult inpatient wards in acute hospitals | SG1 | | |
| Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure | TA314 | | |
| Canagliflozin in combination therapy for treating type 2 diabetes | TA315 | | |
| Teriflunomide for treating relapsing–remitting multiple sclerosis | TA303 | | |
| Pressure ulcers: prevention and management | CG179 | | |
| Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer | TA310 | | |
| Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation | TA311 | | |
| Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis | TA308 | | |
| Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy | TA307 | | |
| Psychosis and schizophrenia in adults: prevention and management | CG178 | | |
| Managing medicines in care homes | SC1 | | |
| Domestic violence and abuse: multi-agency working | PH50 | | |
| Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip | TA304 | | |
| Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion | TA305 | | |
| Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma | TA306 | | |
| Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C | TA106 | | |
| Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people | TA300 | | |
| Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) | TA302 | | |
| Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C | TA75 | | |
| Pazopanib for the first-line treatment of advanced renal cell carcinoma | TA215 | | |
| Varicose veins: diagnosis and management | CG168 | | |
| Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder | TA292 | | |
| Aflibercept solution for injection for treating wet age‑related macular degeneration | TA294 | | |
| Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism | TA287 | | |
| Mirabegron for treating symptoms of overactive bladder | TA290 | | |
| Social anxiety disorder: recognition, assessment and treatment | CG159 | | |
| Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer | TA284 | | |
| Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer | TA285 | | |
| Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) | TA286 | | |
| Omalizumab for treating severe persistent allergic asthma | TA278 | | |
| Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures | TA279 | | |
| Antisocial personality disorder: prevention and management | CG77 | | |
| Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis | TA276 | | |
| Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal) | TA277 | | |
| Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) | TA273 | | |
| Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract | TA272 | | |
| Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma | TA268 | | |
| Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal) | TA270 | | |
| Dronedarone for the treatment of non-permanent atrial fibrillation | TA197 | | |
| Mannitol dry powder for inhalation for treating cystic fibrosis | TA266 | | |
| Ivabradine for treating chronic heart failure | TA267 | | |
| Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours | TA265 | | |
| Alteplase for treating acute ischaemic stroke | TA264 | | |
| Neutropenic sepsis: prevention and management in people with cancer | CG151 | | |
| Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer | TA263 | | |
| Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism | TA261 | | |
| Sickle cell disease: managing acute painful episodes in hospital | CG143 | | |
| Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2 | TA257 | | |
| Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer | TA258 | | |
| Botulinum toxin type A for the prevention of headaches in adults with chronic migraine | TA260 | | |
| Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis | TA254 | | |
| Tocilizumab for the treatment of rheumatoid arthritis | TA247 | | |
| Rituximab for the first-line treatment of stage III-IV follicular lymphoma | TA243 | | |
| Apixaban for preventing venous thromboembolism after hip or knee replacement surgery | TA245 | | |
| Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy | TA242 | | |
| Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer | TA118 | | |
| Service user experience in adult mental health: improving the experience of care for people using adult NHS mental health services | CG136 | | |
| Tocilizumab for the treatment of systemic juvenile idiopathic arthritis | TA238 | | |
| Fulvestrant for the treatment of locally advanced or metastatic breast cancer | TA239 | | |
| Healthcare-associated infections: prevention and control | PH36 | | |
| Mifamurtide for the treatment of osteosarcoma | TA235 | | |
| Ticagrelor for the treatment of acute coronary syndromes | TA236 | | |
| Agomelatine for the treatment of major depressive episodes (terminated appraisal) | TA231 | | |
| Bortezomib and thalidomide for the first‑line treatment of multiple myeloma | TA228 | | |
| Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion | TA229 | | |
| Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction | TA73 | | |
| Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer | TA227 | | |
| Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs | TA225 | | |
| Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma | TA226 | | |
| Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease | TA223 | | |
| Golimumab for the treatment of psoriatic arthritis | TA220 | | |
| Coexisting severe mental illness (psychosis) and substance misuse: assessment and management in healthcare settings | CG120 | | |
| Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia | TA218 | | |
| Food allergy in under 19s: assessment and diagnosis | CG116 | | |
| Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer | TA214 | | |
| Bendamustine for the first-line treatment of chronic lymphocytic leukaemia | TA216 | | |
| Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years | TA213 | | |
| Sedation in under 19s: using sedation for diagnostic and therapeutic procedures | CG112 | | |
| Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events | TA210 | | |
| Prucalopride for the treatment of chronic constipation in women | TA211 | | |
| Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer | TA212 | | |
| Unintentional injuries in the home: interventions for under 15s | PH30 | | |
| Trastuzumab for the treatment of HER2-positive metastatic gastric cancer | TA208 | | |
| Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours | TA209 | | |
| Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours | TA86 | | |
| Bedwetting in under 19s | CG111 | | |
| Denosumab for the prevention of osteoporotic fractures in postmenopausal women | TA204 | | |
| Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal) | TA206 | | |
| Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) | TA207 | | |
| Pregnancy and complex social factors: a model for service provision for pregnant women with complex social factors | CG110 | | |
| Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C | TA200 | | |
| Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor | TA195 | | |
| Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis | TA199 | | |
| Capecitabine for the treatment of advanced gastric cancer | TA191 | | |
| Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer | TA192 | | |
| Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia | TA193 | | |
| Alcohol-use disorders: prevention | PH24 | | |
| Human growth hormone (somatropin) for the treatment of growth failure in children | TA188 | | |
| Improving outcomes for people with skin tumours including melanoma | CSG8 | | |
| Infliximab and adalimumab for the treatment of Crohn's disease | TA187 | | |
| Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes | TA47 | | |
| Donor milk banks: service operation | CG93 | | |
| Topotecan for the treatment of relapsed small-cell lung cancer | TA184 | | |
| Depression in adults with a chronic physical health problem: recognition and management | CG91 | | |
| Topotecan for the treatment of recurrent and stage IVB cervical cancer | TA183 | | |
| Guidance on the use of electroconvulsive therapy | TA59 | | |
| Sunitinib for the treatment of gastrointestinal stromal tumours | TA179 | | |
| Pemetrexed for the first-line treatment of non-small-cell lung cancer | TA181 | | |
| Etanercept and efalizumab for treating moderate to severe plaque psoriasis | TA103 | | |
| Alitretinoin for the treatment of severe chronic hand eczema | TA177 | | |
| Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma | TA178 | | |
| Tenofovir disoproxil for the treatment of chronic hepatitis B | TA173 | | |
| Rituximab for the first-line treatment of chronic lymphocytic leukaemia | TA174 | | |
| Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management | CG84 | | |
| Rivaroxaban for preventing venous thromboembolism after hip or knee replacement surgery | TA170 | | |
| Rehabilitation after critical illness in adults | CG83 | | |
| Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma | TA169 | | |
| Amantadine, oseltamivir and zanamivir for the treatment of influenza | TA168 | | |
| Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence | CG76 | | |
| Borderline personality disorder: recognition and management | CG78 | | |
| Machine perfusion systems and cold static storage of kidneys from deceased donors | TA165 | | |
| Infliximab for acute exacerbations of ulcerative colitis | TA163 | | |
| Mental wellbeing in over 65s: occupational therapy and physical activity interventions | PH16 | | |
| Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin | TA159 | | |
| Dabigatran etexilate for preventing venous thromboembolism after hip or knee replacement surgery | TA157 | | |
| Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza | TA158 | | |
| Routine antenatal anti-D prophylaxis for women who are rhesus D negative | TA156 | | |
| Entecavir for the treatment of chronic hepatitis B | TA153 | | |
| Telbivudine for the treatment of chronic hepatitis B | TA154 | | |
| Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus | TA151 | | |
| Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck | TA145 | | |
| Adalimumab for treating moderate to severe plaque psoriasis | TA146 | | |
| Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) | TA148 | | |
| Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) | TA149 | | |
| Structural neuroimaging in first-episode psychosis | TA136 | | |
| Rituximab for the treatment of relapsed or refractory stage 3 or 4 follicular non-Hodgkin's lymphoma | TA137 | | |
| Infliximab for treating moderate to severe plaque psoriasis | TA134 | | |
| Pemetrexed for the treatment of malignant pleural mesothelioma | TA135 | | |
| Bortezomib monotherapy for relapsed multiple myeloma | TA129 | | |
| Stapled haemorrhoidopexy for the treatment of haemorrhoids | TA128 | | |
| Pemetrexed for the treatment of non-small-cell lung cancer | TA124 | | |
| Acutely ill adults in hospital: recognising and responding to deterioration | CG50 | | |
| Drug misuse in over 16s: opioid detoxification | CG52 | | |
| Drug misuse in over 16s: psychosocial interventions | CG51 | | |
| Varenicline for smoking cessation | TA123 | | |
| Faecal incontinence in adults: management | CG49 | | |
| Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma | TA121 | | |
| Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia | TA119 | | |
| Methadone and buprenorphine for the management of opioid dependence | TA114 | | |
| Naltrexone for the management of opioid dependence | TA115 | | |
| Gemcitabine for the treatment of metastatic breast cancer | TA116 | | |
| Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy | TA117 | | |
| Laparoscopic surgery for colorectal cancer | TA105 | | |
| Improving outcomes for people with brain and other central nervous system tumours | CSG10 | | |
| Docetaxel for the treatment of hormone-refractory metastatic prostate cancer | TA101 | | |
| Capecitabine and oxaliplatin in the adjuvant treatment of stage 3 (Dukes' C) colon cancer | TA100 | | |
| Improving outcomes for people with sarcoma | CSG9 | | |
| Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B | TA96 | | |
| Obsessive-compulsive disorder and body dysmorphic disorder: treatment | CG31 | | |
| Improving outcomes in children and young people with cancer | CSG7 | | |
| HealOzone for the treatment of tooth decay (occlusal pit and fissure caries and root caries) | TA92 | | |
| Guidance on the use of paclitaxel in the treatment of ovarian cancer | TA55 | | |
| Improving outcomes in head and neck cancers | CSG6 | | |
| Dental checks: intervals between oral health reviews | CG19 | | |
| Laparoscopic surgery for inguinal hernia repair | TA83 | | |
| Frequency of application of topical corticosteroids for atopic eczema | TA81 | | |
| Tacrolimus and pimecrolimus for atopic eczema | TA82 | | |
| Fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding | TA78 | | |
| Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia | TA77 | | |
| Pre-hospital initiation of fluid replacement therapy in trauma | TA74 | | |
| Guidance on the use of liquid-based cytology for cervical screening | TA69 | | |
| Human growth hormone (somatropin) in adults with growth hormone deficiency | TA64 | | |
| Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer | TA61 | | |
| Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction | TA52 | | |
| Guidance on the use of ultrasound locating devices for placing central venous catheters | TA49 | | |
| Guidance on the use of trastuzumab for the treatment of advanced breast cancer | TA34 | | |
| Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia | TA29 | | |
| Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease | TA20 | | |
| Guidance on the extraction of wisdom teeth | TA1 | | |